\u23f1 1 min read<\/p>\n
Immitra Bio is a biotech based in Plan-les-Ouates, in the canton of Geneva. It develops in-vivo gene editing therapies designed as off-the-shelf treatments.<\/p>\n
Immitra Bio has closed an upsized pre-seed financing round of 2.4 million francs. The round was led by Backbone Ventures and co-led by OCCIDENT, according to GGBa.<\/p>\n
The platform combines a mutation-agnostic gene editing technology with a digital target identification tool. The approach aims to avoid ex-vivo cell manipulation and stem cell transplantation. It should make it possible to treat all patients with a disease, regardless of their mutation.<\/p>\n
The round also includes Another VC, Kickfund, Venture Kick, Z\u00fcrcher Kantonalbank, FONGIT and the ETH Foundation. Private investors are also taking part.<\/p>\n
The funds will primarily support preclinical proof-of-concept studies for IB-003. This lead candidate targets an inherited anaemia, as a potential one-time curative treatment. The financing will also cover the discovery of new targets and refinement of the platform.<\/p>\n